Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject provides written informed consent before any study-specific evaluation is performed.
- Subject is a healthy adult male or a female of non-childbearing potential between the ages of 18 and 45 years, inclusive.
- Subject has a body mass index of 18.5 to 32 kg/m2, inclusive.
Exclusion Criteria:
- Subject is a woman who is of childbearing potential or is breastfeeding.
- Subject has the presence of an active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose 1 Active
|
|
|
Experimental: Dose 2 Active
|
|
|
Experimental: Dose 3 Active
|
|
|
Experimental: Dose 4 Active
|
|
|
Experimental: Dose 5 Active
|
|
|
Experimental: Dose 6 Active
|
|
|
Experimental: Dose 7 Active
|
|
|
Placebo Comparator: Dose 1 Placebo
|
|
|
Placebo Comparator: Dose 2 Placebo
|
|
|
Placebo Comparator: Dose 3 Placebo
|
|
|
Placebo Comparator: Dose 4 Placebo
|
|
|
Placebo Comparator: Dose 5 Placebo
|
|
|
Placebo Comparator: Dose 6 Placebo
|
|
|
Placebo Comparator: Dose 7 Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse Events
Time Frame: 10 Days
|
10 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- K-312-1.01US
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.